2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibition in Cancer and Viral Research

Executive Summary. 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analog that competitively inhibits glycolysis, resulting in ATP depletion and metabolic stress in targeted cells [APExBIO B1027]. Quantitative in vitro benchmarks show potent cytotoxicity in KIT-positive gastrointestinal stromal tumor (GIST) cell lines, with IC₅₀ values of 0.5 μM in GIST882 and 2.5 μM in GIST430, under standard culture conditions [GTP Solution]. 2-DG has demonstrated robust suppression of porcine epidemic diarrhea virus (PEDV) replication in Vero cells, via inhibition of viral protein translation at early replication stages (Chen et al., 2025). In animal models, 2-DG enhances chemotherapeutic efficacy and delays tumor progression in xenografts of human osteosarcoma and non-small cell lung cancer. The compound is highly soluble (≥105 mg/mL in water) and remains stable at -20°C, making it amenable to diverse experimental workflows [APExBIO].

Biological Rationale

Cancer cells and many viruses depend on elevated glycolytic flux (the "Warburg effect") for energy and biosynthesis, even under normoxic conditions [Glycoprotein-B]. 2-DG, as a structural analog of D-glucose, enters cells via glucose transporters and is phosphorylated by hexokinase to 2-DG-6-phosphate, which cannot proceed through glycolysis. This leads to an accumulation of non-metabolizable intermediates, causing metabolic stress and ATP depletion [GTP Solution]. Such selective metabolic targeting is especially effective in KIT-positive gastrointestinal stromal tumors and other rapidly proliferating malignancies. Moreover, viruses that hijack host glycolytic machinery for replication are susceptible to 2-DG-induced translation blockade (Chen et al., 2025).

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

2-DG exerts its effects by multiple convergent mechanisms:

• Competitive Glycolysis Inhibition: 2-DG competes with D-glucose for uptake and phosphorylation by hexokinase, resulting in inhibition of glycolytic flux and decreased pyruvate and ATP production [GTP Solution].
• Induction of Metabolic Oxidative Stress: ATP depletion from glycolytic blockade leads to increased reliance on mitochondrial oxidative phosphorylation, raising reactive oxygen species (ROS) and cellular stress [Glycoprotein-B].
• Disruption of PI3K/Akt/mTOR Pathway: By lowering ATP availability, 2-DG impairs PI3K/Akt/mTOR-dependent signaling, which is essential for cell survival and proliferation [GTP Solution].
• Viral Replication Inhibition: 2-DG impairs viral protein translation during the early stages of PEDV replication in Vero cells, thus blocking viral genome amplification (Chen et al., 2025).

Evidence & Benchmarks

• 2-DG induces cytotoxicity in KIT-positive GIST882 and GIST430 cell lines with IC₅₀ values of 0.5 μM and 2.5 μM, respectively, after 24 hours of exposure (https://www.apexbt.com/2-deoxy-d-glucose.html).
• In Vero cells, 2-DG at micromolar concentrations suppresses PEDV replication by inhibiting viral protein translation (Chen 2025, https://doi.org/10.1016/j.phymed.2025.157684).
• In nude mouse xenograft models of human osteosarcoma and non-small cell lung cancer, co-administration of 2-DG with Adriamycin or Paclitaxel significantly slows tumor growth (GTP Solution).
• 2-DG is soluble at ≥105 mg/mL in water, ≥2.37 mg/mL in ethanol (with warming and ultrasound), and ≥8.2 mg/mL in DMSO, facilitating diverse in vitro and in vivo protocols (APExBIO).
• Typical working concentrations are 5–10 mM for 24-hour cell culture treatments, providing robust inhibition of glycolytic flux (PeptideBridge).

For additional discussion on immunometabolic checkpoint modulation, see "2-Deoxy-D-glucose (2-DG): Metabolic Checkpoint Modulation"—this article extends those findings with new antiviral data and solubility benchmarks.

Applications, Limits & Misconceptions

2-DG is deployed in oncology, virology, and metabolic pathway research as a precise modulator of glucose metabolism. Its activity has been validated in preclinical settings for:

• Cancer Therapy Research: Targeting metabolic vulnerabilities in solid tumors (notably KIT-positive GIST and non-small cell lung cancer).
• Viral Replication Inhibition: Blocking early-stage viral protein synthesis in PEDV and related viruses.
• Metabolic Pathway Studies: Dissecting glycolytic and oxidative phosphorylation dependencies in immune cell reprogramming (Chen et al., 2025).

For a broader context on tumor microenvironment effects, "2-Deoxy-D-glucose: Precision Modulation of Tumor and Viral Metabolism" details how this agent disrupts energy homeostasis beyond standard glycolysis inhibition. The current article further clarifies specific dosing and solubility guidelines.

Common Pitfalls or Misconceptions

• 2-DG is not a universal cytotoxin; its efficacy varies by cell type and metabolic state.
• Long-term storage of 2-DG solutions (>1 month) at room temperature leads to degradation and loss of potency.
• 2-DG does not inhibit mitochondrial respiration directly; its effects on oxidative phosphorylation are secondary to glycolytic blockade.
• Not all viruses are equally sensitive to 2-DG; activity has been confirmed for PEDV and select RNA viruses.
• High doses in animal models may cause hypoglycemia-like symptoms—appropriate controls are required.

Workflow Integration & Parameters

2-DG is supplied by APExBIO as product B1027, with high purity and batch-to-batch consistency. For in vitro assays, dissolve at ≥105 mg/mL in water; ethanol and DMSO are alternatives for specific protocols requiring organic solvents. Recommended storage is at -20°C, avoiding light and repeated freeze-thaw cycles. For cytotoxicity and metabolic flux assays, typical concentrations are 5–10 mM, with incubation periods ranging from 6–48 hours. In vivo, dosing regimens must be titrated to avoid systemic toxicity and account for glucose homeostasis. For advanced workflow integration, see "Rewiring Tumor and Immune Metabolism"; this article adds specific virology application guidance not covered in prior reviews.

Conclusion & Outlook

2-Deoxy-D-glucose (2-DG) is an indispensable metabolic pathway research tool and glycolysis inhibitor, with robust evidence for its role in cancer and viral replication studies. Its precise mechanism, validated benchmarks, and high solubility profile enable reproducible results in both cellular and animal models. Future directions include combination regimens with targeted therapies and immunometabolic modulators. For verified protocols and ordering, visit the APExBIO product page.